Previous studies have reported that FXYD-domain-containing ion-transport regulator 5 (FXYD5) enhances the resistance of HCC cells to sorafenib by activating the AKT/mTOR-signaling pathway [44]. Here, FXYD5 is linked to hepatocellular carcinoma.